Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular Degeneration
Status: Recruiting
Location: See all (11) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Healthy Volunteers: f
View:
• Are ≥60 years of age at the time of consent.
• Are willing and able to understand and provide written informed consent.
• Are willing and able to return for scheduled treatment and follow-up examinations.
• Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
• Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
• Absence of signs of non-exudative MNV.
• Additional Ocular Inclusion Criteria for both eyes.
• Meet certain genotype criteria for risk of AMD.
Locations
United States
Arizona
Retina Macula Institute of AZ
RECRUITING
Scottsdale
California
The Retina Partners
RECRUITING
Encino
Retinal Consultants Medical Group
RECRUITING
Sacramento
Retina Consultants San Diego
RECRUITING
San Diego
Texas
Star Retina
RECRUITING
Burleson
Retina Center of Texas
RECRUITING
Southlake
Utah
University of Utah John A. Moran Eye Center
RECRUITING
Salt Lake City
Other Locations
Australia
Cerulea Clinical Trials
ACTIVE_NOT_RECRUITING
East Melbourne
Sydney Retina Clinic and Day Surgery
ACTIVE_NOT_RECRUITING
Sydney
Israel
Rambam Medical Center
RECRUITING
Haifa
Tel-Aviv Sourasky Medical Center, Ophthalmology Division
RECRUITING
Tel Aviv
Contact Information
Primary
Anne Fung, MD
Voy101clinical@perceivebio.com
(800) 867-7960
Time Frame
Start Date: 2023-06-21
Estimated Completion Date: 2028-03
Participants
Target number of participants: 60
Treatments
Experimental: VOY-101
Single intravitreal injection of VOY-101
No_intervention: Controll
Fellow Eye
Related Therapeutic Areas
Sponsors
Leads: Perceive Biotherapeutics, Inc.